Circulating Tumor Cells: Application as a Biomarker for Molecular Characterization and Predictor of Survival in an All-Comer Solid Tumor Phase I Clinical Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Bao, Haifeng ^a   Burke, Patricia A ^a   Huang, Jiaqi ^a   Chen, Xiaoru ^a   Brohawn, Philip Z ^a   Yao, Yihong ^a   Lechleider, Robert J ^a   Sikorski, Robert S ^a   Buzoianu, Manuela ^a   Zhang, Jianliang ^a   Shi, Xiaoqing ^a   Richman, Laura K ^a   LaVallee, Theresa M ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOVETUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST TUMOR; CANCER PROGNOSIS; CANCER SCREENING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLON TUMOR; DISEASE ACTIVITY; DRUG DOSE ESCALATION; ENDOMETRIUM TUMOR; FEMALE; GENE TARGETING; HUMAN; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; OVARY TUMOR; OVERALL SURVIVAL; PATIENT CODING; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TUMOR DIAGNOSIS;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROBABILITY; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882605509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058557     Document Type: Article

References (28)

1. Xu W, Cao L, Chen L, Li J, Zhang XF, et al. (2011) Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 17: 3783-3793. doi:10.1158/1078-0432.CCR-10-0498. PubMed: 21527564.
2. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, et al. (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904. doi:10.1158/1078-0432.CCR-04-0378. PubMed: 15501967.
3. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229. doi:10.1093/annonc/mdn786. PubMed: 19282466.
4. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309. doi:10.1158/1078-0432.CCR-08-0872. PubMed: 18829513.
5. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29: 1556-1563. doi:10.1200/JCO.2010.28.7045. PubMed: 21422424.
6. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. (2006) Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403-6409. doi:10.1158/1078-0432.CCR-05-1769. PubMed: 17085652.
7. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, et al. (2008) Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26: 1208-1215. doi:10.1200/JCO.2007.13.6523. PubMed: 18323545.
8. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, et al. (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115: 581-590. doi:10.1007/s10549-008-0143-x. PubMed: 18679793.
9. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101: 9393-9398. doi:10.1073/pnas.0402993101. PubMed: 15194824.
10. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377. doi:10.1056/NEJMoa0800668. PubMed: 18596266.
11. Bauman JE, Eaton KD, Martins RG, (2007) Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin Cancer Res 13: s4632-s4636. doi:10.1158/1078-0432.CCR-07-0212. PubMed: 17671155.
12. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F, (2005) Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 7: R788-R795. doi:10.1186/bcr1304. PubMed: 16168125.
13. Alvarez RH, Kantarjian HM, Cortes JE, (2006) Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81: 1241-1257. doi:10.4065/81.9.1241. PubMed: 16970222.
14. nd EORTC-NCI-AACR. Symposium.
15. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, et al. (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13: 920-928. doi:10.1158/1078-0432.CCR-06-1695. PubMed: 17289886.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216. doi:10.1093/jnci/92.3.205. PubMed: 10655437.
17. Kaplan Edward L, Meier Paul (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481 doi:10.1080/01621459.1958.10501452.
18. Klein, John P, Moeschberger Melvin L (2003) Survival analysis. techniques for censored and truncated Data, 2nd edn. Springer Verlag.
19. Huang J, Brohawn P, Bao H, Burke P, Chen X, et al. (2010) Molecular characterization of circulating tumor cells using fluidigm biomark dynamic array. Proc Am Assoc Cancer Res 51: 190.
20. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, et al. (2005) Global gene expression profiling of circulating tumor cells. Cancer Res 65: 4993-4997. doi:10.1158/0008-5472.CAN-04-4330. PubMed: 15958538.
21. Paterlini-Brechot P, Benali NL, (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253: 180-204. doi:10.1016/j.canlet.2006.12.014. PubMed: 17314005.
22. Van da I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, et al. (2010) Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102: 276-284. doi:10.1038/sj.bjc.6605472. PubMed: 19953098.
23. Tibbe AG, Miller MC, Terstappen LW, (2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71: 154-162. PubMed: 17200956.
24. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, et al. (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21: 729-733. doi:10.1093/annonc/mdp391. PubMed: 19850639.
25. Olmos D, Baird RD, Yap TA, Massard C, Pope L, et al. (2011) Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res 17: 5188-5196. doi:10.1158/1078-0432.CCR-10-3019. PubMed: 21531820.
26. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, et al. (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397. doi:10.1093/jnci/djq310. PubMed: 20826737.
27. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, et al. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168-177. doi:10.1016/j.stem.2009.05.019. PubMed: 19664991.
28. Sieuwerts AM, Kraan J, Bolt J, van der SP, Elstrodt F, et al. (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101: 61-66. doi:10.1093/jnci/djn419. PubMed: 19116383.